Phase 3 Clinical Trials With Primary Completion Dates in November 2016
This is a list of Phase 3 trials with primary completion dates in November 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | 2016-11-01 | Phase 3 | NCT02558374 | Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension |
| CBPO | China Biologic Products, Inc. | 2016-11-01 | Phase 3 | NCT02623556 | Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen |
| CLDX | Celldex Therapeutics, Inc. | 2016-11-01 | Phase 3 | NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma |
| FGEN | FibroGen, Inc | 2016-11-01 | Phase 3 | NCT02652806 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease |
| HZNP | Horizon Pharma plc | 2016-11-01 | Phase 3 | NCT02415127 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia |
| MMSI | Merit Medical Systems, Inc. | 2016-11-01 | Phase 3 | NCT02159898 | EndoMAXX EVT Compared to EndoMAXX |
| NWBO | Northwest Biotherapeutics, Inc. | 2016-11-01 | Phase 3 | NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer |
| ONTX | Onconova Therapeutics, Inc. | 2016-11-01 | Phase 3 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |
| OTIC | Otonomy, Inc. | 2016-11-01 | Phase 3 | NCT02801370 | Phase 3 Study of OTO-201 in Acute Otitis Externa |
| PCRX | Pacira Pharmaceuticals, Inc. | 2016-11-01 | Phase 3 | NCT02713230 | Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery |
| PCRX | Pacira Pharmaceuticals, Inc. | 2016-11-01 | Phase 3 | NCT02713178 | Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty |
| PTCT | PTC Therapeutics, Inc. | 2016-11-01 | Phase 3 | NCT02139306 | Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) |
| REPH | Recro Pharma, Inc. | 2016-11-01 | Phase 3 | NCT02678286 | Evaluation of N1539 Following Abdominoplasty Surgery |
| RPTP | Raptor Pharmaceutical Corp. | 2016-11-01 | Phase 3 | NCT01744782 | Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis |
| TARO | Taro Pharmaceutical Industries Ltd. | 2016-11-01 | Phase 3 | NCT02933866 | Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis |